top of page

Overview of Neurofibromatosis

Neurofibromatosis is a group of genetic disorders that cause tumors to form on nerve tissue. The tumors, which can develop anywhere in the nervous system, including the brain, spinal cord, and nerves, are typically benign. However, in some cases the tumors can become malignant. The disorder, typically diagnosed during childhood or early adulthood, can cause hearing loss, learning impairments, heart and blood vessel complications, vision loss and severe pain.

There are three types of neurofibromatosis, including neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. Neurofibromatosis 1 (NF1) is the most common and typically develops during childhood. Symptoms associated with NF1 include six or more light brown spots on the skin that measure more than 5 millimeters in diameter in children and more than 15 millimeters across in adolescents and adults, freckling in the armpit or groin, two or more growths on the iris of the eye, soft bumps on or under the skin, bone deformities like a curved spine and learning disabilities. Neurofibromatosis 2 (NF2) is much less common and can cause gradual hearing loss, ringing in the ears and poor balance. Schwannamatosis is rare and causes severely painful tumors to develop on cranial, spinal and peripheral nerves.

The mutated gene that causes neurofibromatosis is commonly inherited, but it can also result from spontaneous mutations.

There is no cure for neurofibromatosis, so treatment focuses on ongoing pain management and dealing with complications as they develop. In some cases, surgery may be necessary to remove large tumors or tumors that press on a nerve. Once tumors are removed, pain often subsides, but will recur once new tumors form.

Findings: Effects of Cannabis on Neurofibromatosis

Cannabis has been found to have anti-tumor efforts, which suggests it may be helpful in limiting the development and growth of tumors caused by neurofibromatosis. One study found that two children with neurofibromatosis 1 saw their tumors clearly regress during a three-year period where no conventional treatment was used but cannabis was consumed via inhalation (Foroughi, Hendson, Sargent & Steinbok, 2011). Two major cannabinoids found in cannabis, tetrahydrocannabinol (THC) and cannabidiol (CBD), have shown to be beneficial for inhibiting tumors. CBD has demonstrated that by activating the CB1 and CB2 receptors, it inhibits tumor cell viability, invasion, spreading and growth (McAllister, Soroceanu & Desprez, 2015). One study found that both THC and CBD have antitumor effects, but that CBD is the most potent inhibitor (Ligresti, et al., 2006).

Cannabis can help those with neurofibromatosis manage pain. Cannabis has demonstrated the ability to significantly lower pain, even showning it can help curtail pain that has proven refractory to other treatments (Boychuck, Goddard, Mauro & Orellana, 2015) (Wallace, et al., 2015) (Lynch & Campbell, 2011). Cannabis use has been found to be prevalent among the chronic pain population, with improvements in pain, sleep and mood being the most frequently reported reasons for use (Ware, et al., 2003). THC and CBD have shown to help in the management of pain. They activate the CB1 and CB2 receptors, which regulate the release of neurotransmitter and central nervous system immune cells to manage pain levels (Woodhams, Sagar, Burston & Chapman, 2015).


  1. Boychuck, D.G., Goddard, G., Mauro, G., and Orellana, M.F. (2015 Winter). The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review. Journal of Oral & Facial Pain and Headache, 29(1), 7-14. Retrieved from

  2. Foroughi, M., Hendson, G., Sargent, M.A., and Steinbok, P. (2011, April). Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas–possible role of Cannabis inhalation. Child’s Nervous System, 27(4), 671-9. Retrieved from

  3. Ligresti, A., Moriello, A.S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., and Di Marzo, V. (2006, September). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. Journal of Pharacologogy and Experimental Therapeutics, 318(3), 1375-87. Retrieved from

  4. Lynch, M.E., and Campbell, F. (2011, November). Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology, 72(5), 735-744. Retrieved from

  5. McAllister, S.D., Soroceanu, L., and Desprez, P.Y. (2015, June). The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. Journal of Neuroimmune Pharmacology, 10(2), 255-67. Retrieved from

  6. Neurofibromatosis. (2013, January 3). Mayo Clinic. Retrieved from

  7. Neurofibromatosis Fact Sheet. (2015, July 27). National Institute of Neurological Disorders and Stroke. Retrieved from

  8. Wallace, M.S., Marcotte, T.D., Umlauf, A., Gouaux, B., and Atkinson, J.H. (2015, July). Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. Journal of Pain, 16(7), 616-27. Retrieved from

  9. Ware, M.A., Doyle, C.R., Woods, R., Lynch, M.E., and Clark, A.J. (2003, March). Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain, 102(1-2). Retrieved from

  10. Woodhams, S.G., Sagar, D.R., Burston, J.J., and Chapman, V. (2015). The role of the endocannabinoid system in pain. Handbook of Experimental Pharmacology, 227, 119-43. Retrieved from

bottom of page